First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer

AIM: To investigate activity, toxicity, and prognostic factors for survival of erlotinib and fixed dose-rate gemcitabine (FDR-Gem) in advanced pancreatic cancer. METHODS: We designed a single-arm prospective, multicentre, open-label phase II study to evaluate the combination of erlotinib (100 mg/d,...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Vaccaro, Vanja, Bria, Emilio, Sperduti, Isabella, Gelibter, Alain, Moscetti, Luca, Mansueto, Giovanni, Ruggeri, Enzo Maria, Gamucci, Teresa, Cognetti, Francesco, Milella, Michele
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Baishideng Publishing Group Co., Limited 2013
Gaiak:
Brief Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3725375/
https://ncbi.nlm.nih.gov/pubmed/23901226
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v19.i28.4511
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak